Last week, the French vaccine maker Valneva announced promising phase III trial results of its inactivated Covid-19 vaccine: a well-established technology that could confer broader immunity to the virus than shots currently on the market.
Valneva’s vaccine candidate consists of a killed or ‘inactivated’ version of SARS-CoV-2, the virus responsible for Covid-19. The vaccine was tested in adults aged 18 and up in a phase III trial and its protection was compared to AstraZeneca’s Covid-19 vaccine.
According to the trial results, participants treated with Valneva’s candidate experienced fewer side effects than those given AstraZeneca’s vaccine, particularly those over 30. Additionally, the group given Valneva’s candidate carried more neutralizing antibodies against SARS-CoV-2 in their blood.
Covid-19 vaccines currently on the market in Europe are based on either adenoviral vectors, including vaccines from AstraZeneca and Johnson & Johnson, or newer messenger mRNA (mRNA) technology including vaccines from BioNTech/Pfizer and Moderna. Their exclusive target is the spike protein on the surface of the virus,
The post Valneva’s Inactivated Covid-19 Vaccine Aces Phase III Trial appeared first on Labiotech.eu.
© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.